Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TAPENTADOL vs ACETAMINOPHEN AND HYDROCODONE BITARTRATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Tapentadol is a centrally acting analgesic with a dual mechanism of action: mu-opioid receptor agonist and norepinephrine reuptake inhibitor.
Acetaminophen: analgesic and antipyretic effects via inhibition of cyclooxygenase (COX) and activation of descending serotonergic pathways; central action. Hydrocodone: mu-opioid receptor agonist; activates G-protein coupled receptors to modulate pain perception and emotional response.
Management of moderate to severe acute pain,Management of neuropathic pain associated with diabetic peripheral neuropathy,Management of chronic pain
Moderate to moderately severe pain,Cough suppression (hydrocodone; off-label)
Immediate-release tablets: 50-100 mg orally every 4-6 hours as needed for pain; maximum 600 mg per day. Extended-release tablets: 50-250 mg orally twice daily (every 12 hours); maximum 500 mg per day.
1-2 tablets (containing 5-10 mg hydrocodone and 300-325 mg acetaminophen) orally every 4-6 hours as needed for pain; maximum 8 tablets per day.
Terminal elimination half-life is approximately 4 hours (range 3-5 hours) for immediate-release; for extended-release, effective half-life is about 4-6 hours due to prolonged absorption.
Acetaminophen: 2-3 hours in adults; prolonged in hepatic impairment (up to 5 hours). Hydrocodone: 3.8-4.5 hours (range 3-5 hours) in healthy adults; prolonged in elderly or hepatic/renal impairment. Clinical context: repeated dosing may require extended intervals in renal impairment.
Extensively metabolized via conjugation (primarily glucuronidation) and by CYP2C9 and CYP2C19 to a minor extent. Major metabolites are inactive.
Acetaminophen: primarily via glucuronidation (UGT1A1, UGT1A6, UGT1A9) and sulfation; minor CYP2E1 oxidation to NAPQI (toxic metabolite). Hydrocodone: CYP3A4 and CYP2D6; N-demethylation to norhydrocodone; O-demethylation to hydromorphone (CYP2D6).
Primarily renal: approximately 95% of the dose is excreted in urine (60% as tapentadol glucuronide, 15% as unchanged tapentadol, and 20% as other metabolites); less than 3% excreted in feces.
Acetaminophen: primarily renal excretion of conjugated metabolites (glucuronide and sulfate) with approximately 5% excreted unchanged. Hydrocodone: renal excretion as unchanged drug and metabolites (O-demethylated and N-demethylated); total renal excretion accounts for about 60-70% of dose (parent and metabolites). Biliary/fecal elimination is minimal.
Approximately 20% bound to plasma proteins (primarily albumin).
Acetaminophen: 10-25% bound, nonspecific binding to albumin. Hydrocodone: 25-50% bound, primarily to albumin and alpha-1-acid glycoprotein.
540 L (approximately 7.7 L/kg for a 70 kg adult), indicating extensive tissue distribution.
Acetaminophen: 0.8-1.0 L/kg, indicating distribution into total body water; clinically relevant for loading dose calculations. Hydrocodone: 3.0-4.0 L/kg, suggesting extensive tissue distribution; higher Vd may require higher loading doses but has no clinical target.
Oral: approximately 32% due to first-pass metabolism; intravenous: 100%.
Acetaminophen: oral bioavailability 85-95% (first-pass metabolism minimal). Hydrocodone: oral bioavailability about 25-45% due to first-pass hepatic metabolism; significant interindividual variability.
Creatinine clearance (Cr Cl) 30-80 m L/min: No adjustment needed. Cr Cl <30 m L/min: Not recommended (extended-release) or use with caution and reduce dose by 50% (immediate-release). Hemodialysis: Not recommended.
GFR 10-50 m L/min: administer every 6 hours; GFR <10 m L/min: administer every 8 hours; avoid in severe impairment due to acetaminophen metabolite accumulation.
Child-Pugh Class A: No adjustment. Child-Pugh Class B: Reduce dose by 50% and increase dosing interval to every 8 hours (immediate-release) or every 12 hours (extended-release). Child-Pugh Class C: Contraindicated.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50% or extend interval; Child-Pugh C: use with caution, avoid if possible, consider alternative therapy.
Safety and efficacy not established in children <18 years; not recommended.
Dosing based on hydrocodone component: 0.1-0.2 mg/kg/dose every 4-6 hours; maximum daily acetaminophen limit: 75 mg/kg/day; not recommended for children <2 years.
Start at low end of dosing range; monitor for CNS effects, constipation, and respiratory depression. Immediate-release: 50 mg every 6 hours initially; extended-release: not recommended for opioid-naïve elderly.
Initiate at lowest effective dose, typically 1 tablet (2.5-5 mg hydrocodone) every 6 hours; monitor for respiratory depression and acetaminophen toxicity; avoid in frail elderly with hepatic impairment.
Risk of addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion; neonatal opioid withdrawal syndrome; risks from concomitant use with benzodiazepines or other CNS depressants; and interactions with drugs affecting cytochrome P450 isoenzymes.
Addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion of acetaminophen; neonatal opioid withdrawal syndrome; interaction with alcohol; risk of medication errors.
Addiction, abuse, and misuse; life-threatening respiratory depression; neonatal opioid withdrawal syndrome; risks from concomitant use with benzodiazepines or other CNS depressants; severe hypotension; seizures; risk of serotonin syndrome; adrenal insufficiency; and withdrawal.
Hepatotoxicity from acetaminophen overdose; respiratory depression; increased intracranial pressure; CNS depression; elderly/debilitated patients; renal impairment; opioid-induced hyperalgesia; serotonin syndrome; interaction with CNS depressants; risk of adrenal insufficiency; severe hypotension; use in patients with gastrointestinal obstruction; convulsion risk; severe hepatic impairment; urinary retention; acute abdominal conditions; hypothyroidism; prostatic hypertrophy; adrenocortical insufficiency; pregnancy/lactation; pediatric use; geriatric use; renal impairment; hepatic impairment.
Significant respiratory depression; acute or severe bronchial asthma in an unmonitored setting or in absence of resuscitative equipment; known or suspected gastrointestinal obstruction; concurrent use of MAOIs or within 14 days; hypersensitivity to tapentadol.
Hypersensitivity to acetaminophen or hydrocodone; significant respiratory depression; acute or severe bronchial asthma; upper airway obstruction; known or suspected gastrointestinal obstruction; paralytic ileus; concomitant use of monoamine oxidase inhibitors (MAOIs) or within 14 days; severe hepatic impairment (acetaminophen toxicity risk); acute alcoholism.
No specific food interactions. Alcohol should be avoided due to additive CNS depressant effects.
Avoid alcohol consumption during therapy; ethanol increases acetaminophen hepatotoxicity risk and enhances CNS depression. Grapefruit juice may inhibit CYP2D6 (minor effect) but no significant clinical interaction. No other specific food restrictions.
First trimester: Limited data, no clear evidence of major malformations in humans, but opioid use associated with neural tube defects in some studies. Second and third trimesters: Chronic use may lead to fetal opioid dependence and neonatal opioid withdrawal syndrome (NOWS). Avoid prolonged use near term due to risk of respiratory depression at birth.
First trimester: Acetaminophen considered low risk; hydrocodone is a pregnancy category C drug. Data from retrospective studies suggest a small increased risk of certain congenital malformations (e.g., neural tube defects, cleft palate) with first trimester opioid use, but absolute risk is low. Second trimester: Low risk as above. Third trimester: Prolonged use of hydrocodone can cause neonatal opioid withdrawal syndrome (NOWS); acetaminophen is safe. Use only if benefit outweighs risk.
Excreted into breast milk in low concentrations (M/P ratio approximately 0.8). Infant exposure is low but may cause sedation or respiratory depression in neonates, especially with high maternal doses or prolonged use. Caution advised; monitor infant for signs of sedation or poor feeding.
Acetaminophen excretion in breast milk is low (M/P ratio ~0.9). Hydrocodone is excreted in small amounts (M/P ratio ~2.1). The relative infant dose is estimated to be 2.5-3.5% of maternal weight-adjusted dose for hydrocodone. Monitor infant for sedation and respiratory depression. Consider benefit to mother and potential neonatal opioid withdrawal if used chronically.
No specific dose adjustments recommended, but pharmacokinetic changes in pregnancy (increased clearance, volume of distribution) may require higher doses to maintain analgesia. Use lowest effective dose for shortest duration. Avoid chronic use; consider opioid-sparing strategies.
During pregnancy, increased plasma volume and enhanced hepatic clearance may reduce serum concentrations of both drugs. However, dosing adjustments are not routinely recommended due to risk of undertreatment. Use the lowest effective dose of hydrocodone for the shortest duration. For acetaminophen, maximum daily dose should not exceed 3000 mg to avoid hepatotoxicity.
Tapentadol is a dual-mechanism opioid agonist and norepinephrine reuptake inhibitor. It has a lower incidence of opioid-induced nausea and vomiting compared to morphine. Avoid use in patients with severe hepatic impairment. Maximum daily dose is 600 mg. Do not crush extended-release tablets. Discontinuation should be gradual to avoid withdrawal. Serotonin syndrome risk when combined with serotonergic agents.
Acetaminophen-hydrocodone is contraindicated in severe respiratory depression, acute or severe bronchial asthma, and known hypersensitivity. Monitor for respiratory depression, especially in elderly or debilitated patients. Avoid use with other acetaminophen-containing products to prevent hepatotoxicity. Hydrocodone is a prodrug metabolized by CYP2D6 to hydromorphone; CYP2D6 ultrarapid metabolizers may experience toxicity. Use with caution in patients with head injury, increased intracranial pressure, or severe hepatic impairment. Naloxone is the reversal agent for opioid effects; acetylcysteine for acetaminophen overdose.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Do not crush, chew, or dissolve tablets; swallow whole.,Avoid alcohol and other CNS depressants (e.g., sedatives, tranquilizers) as they may increase risk of serious side effects like respiratory depression.,Dizziness or drowsiness may occur; avoid driving or operating machinery until you know how the medication affects you.,Do not stop abruptly; taper dose under medical supervision to prevent withdrawal symptoms.,Common side effects include nausea, vomiting, constipation, dizziness, and headache.,Report symptoms of serotonin syndrome (e.g., agitation, hallucinations, rapid heartbeat, fever, muscle stiffness) immediately.,Keep out of reach of children; misuse can cause overdose and death.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Avoid alcohol and other CNS depressants (e.g., benzodiazepines, sedatives) as they increase risk of severe drowsiness and respiratory depression.,Do not exceed 4000 mg of acetaminophen per day from all sources; check labels of other medications.,This medication may cause dizziness or drowsiness; avoid driving or operating heavy machinery until you know how it affects you.,Store securely out of reach of others, especially children, as misuse can cause overdose and death.,Do not stop abruptly; withdrawal may occur. Taper under medical supervision.,Contact emergency if you experience trouble breathing, extreme drowsiness, or signs of allergic reaction.,Report any history of substance abuse, as this medication has abuse potential.
"The combination of Propiverine, an anticholinergic agent used for overactive bladder, with Tapentadol, a mu-opioid receptor agonist and norepinephrine reuptake inhibitor, can result in additive anticholinergic effects. This increases the risk of severe adverse effects such as urinary retention, constipation, dry mouth, blurred vision, and central nervous system depression. Elderly patients are especially susceptible to these effects, which may lead to falls, cognitive impairment, or anticholinergic toxicity."
"Lorazepam, a benzodiazepine, potentiates the central nervous system (CNS) depressant effects of tapentadol, an opioid analgesic, by enhancing GABAergic activity and reducing neurotransmitter release. This additive pharmacodynamic interaction can lead to excessive sedation, respiratory depression, profound hypotension, and increased risk of coma or death, particularly in elderly or debilitated patients. Clinical outcomes include heightened CNS depression, impaired psychomotor function, and potential for opioid-induced respiratory compromise when used concomitantly."
"Zonisamide, a sulfonamide anticonvulsant, potentiates the central nervous system (CNS) depressant effects of tapentadol, a mu-opioid agonist and norepinephrine reuptake inhibitor. This additive pharmacodynamic interaction can lead to excessive sedation, respiratory depression, and impaired psychomotor function, particularly when initiating or titrating either drug. Patients may experience increased risk of falls, cognitive impairment, and potentially life-threatening respiratory compromise."
"Hydrocodone, an opioid agonist, and scopolamine, an anticholinergic agent, both exhibit central nervous system (CNS) depressant effects. When co-administered, their combined activity can lead to additive CNS depression, resulting in enhanced sedation, respiratory depression, and cognitive impairment. This interaction may also increase the risk of constipation and urinary retention due to additive anticholinergic effects from both drugs."
"Pargyline, a monoamine oxidase inhibitor (MAOI), irreversibly inhibits the metabolism of amines, leading to increased intraneuronal stores of norepinephrine. Hydrocodone, a semisynthetic opioid, can release these stored catecholamines, potentially causing a hypertensive crisis, serotonin syndrome, or CNS excitation. Coadministration may also result in excessive sedation and respiratory depression due to additive CNS depressant effects, requiring immediate clinical attention."
"Hydrocodone, an opioid agonist, and oxprenolol, a non-selective beta-adrenoceptor antagonist, are both central nervous system (CNS) depressants. Their combined use can lead to additive CNS depression, resulting in excessive sedation, respiratory depression, hypotension, and bradycardia. This interaction is particularly dangerous in patients with compromised cardiac or respiratory function, potentially leading to coma or death."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about TAPENTADOL vs ACETAMINOPHEN AND HYDROCODONE BITARTRATE, answered by our medical review team.
TAPENTADOL is a Opioid Agonist that works by Tapentadol is a centrally acting analgesic with a dual mechanism of action: mu-opioid receptor agonist and norepinephrine reuptake inhibitor.. ACETAMINOPHEN AND HYDROCODONE BITARTRATE is a Opioid Agonist that works by Acetaminophen: analgesic and antipyretic effects via inhibition of cyclooxygenase (COX) and activation of descending serotonergic pathways; central action. Hydrocodone: mu-opioid receptor agonist; activates G-protein coupled receptors to modulate pain perception and emotional response.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between TAPENTADOL and ACETAMINOPHEN AND HYDROCODONE BITARTRATE depend on the specific clinical indication. These are both Opioid Agonist agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of TAPENTADOL is: Immediate-release tablets: 50-100 mg orally every 4-6 hours as needed for pain; maximum 600 mg per day. Extended-release tablets: 50-250 mg orally twice daily (every 12 hours); maximum 500 mg per day.. The standard adult dose of ACETAMINOPHEN AND HYDROCODONE BITARTRATE is: 1-2 tablets (containing 5-10 mg hydrocodone and 300-325 mg acetaminophen) orally every 4-6 hours as needed for pain; maximum 8 tablets per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining TAPENTADOL and ACETAMINOPHEN AND HYDROCODONE BITARTRATE. Hydrocodone may increase the central nervous system depressant (CNS depressant) activities of Tapentadol. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. TAPENTADOL is classified as Category A/B. First trimester: Limited data, no clear evidence of major malformations in humans, but opioid use associated with neural tube defects in some studies. Second and third trimesters: . ACETAMINOPHEN AND HYDROCODONE BITARTRATE is classified as Category D/X. First trimester: Acetaminophen considered low risk; hydrocodone is a pregnancy category C drug. Data from retrospective studies suggest a small increased risk of certain congenital. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.